WO2017129024A1 - 一种维利帕尼晶型a及其制备方法 - Google Patents

一种维利帕尼晶型a及其制备方法 Download PDF

Info

Publication number
WO2017129024A1
WO2017129024A1 PCT/CN2017/071619 CN2017071619W WO2017129024A1 WO 2017129024 A1 WO2017129024 A1 WO 2017129024A1 CN 2017071619 W CN2017071619 W CN 2017071619W WO 2017129024 A1 WO2017129024 A1 WO 2017129024A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
acid
aqueous solution
crystal form
velipani
Prior art date
Application number
PCT/CN2017/071619
Other languages
English (en)
French (fr)
Inventor
彭俊
朱志平
院兴
夏荣
郑德平
Original Assignee
重庆医药工业研究院有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 重庆医药工业研究院有限责任公司 filed Critical 重庆医药工业研究院有限责任公司
Publication of WO2017129024A1 publication Critical patent/WO2017129024A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention belongs to the technical field of medicinal chemistry, and in particular relates to crystal form A of velipani and a preparation method thereof.
  • Willipani is a poly ADP-ribose polymerase (PARP) inhibitor developed by Abbott, AbbVie, for cancer treatment, mainly triple-negative breast cancer and metastatic squamous non-small cell lung cancer.
  • PARP poly ADP-ribose polymerase
  • Patent CN101821269 reports the crystal form characteristics and preparation method of Form 2, which completely dissolves velipani in methanol and then concentrates under reduced pressure at about 35 °C. The method has high sample yield, but has no impurity removing effect, and the finished product has dark color; in the concentration process, the purity of the product is obviously decreased, and the purity is about 97%; and the reproducibility experiment also finds that the method obtains a single type 2 crystal. Poor reproducibility.
  • Patent CN101821270 reports the crystal form characteristics and preparation method of crystal form 1.
  • the method is cumbersome to operate, the solvent used is n-butanol, The boiling point of n-heptane is high, and the high temperature in the concentration process tends to cause the purity of the product to decrease.
  • the yield of the method is low, about 30-40%, and the purity is about 98%.
  • the vilipani dihydrochloride is dissolved in water, the pH is adjusted by a gradient, and the crystal is slowly decrystallized.
  • the method is cumbersome to operate, the pH value is strictly controlled, and the process reproducibility is difficult. At the same time, the process has a long production cycle and a high production cost.
  • the invention provides a stable velipani new crystal form and a preparation method thereof. Compared with the prior crystal form 1 and the crystal form 2, the crystal form preparation method of the invention is simple, the yield is high, and the purity is over 99%. The crystal form is stable in quality.
  • the crystal form A has the advantages of simple preparation method, high yield, high purity and stable crystal quality.
  • a velipani form A of the present invention has a 2 ⁇ value of X93 powder diffraction pattern of 9.39 ⁇ 0.2°, 13.38 ⁇ 0.2°, 17.25 ⁇ 0.2°, 17.70 ⁇ 0.2°, 18.94 ⁇ 0.2°, 21.79 ⁇ 0.2. Characteristic diffraction peaks at °, 22.77 ⁇ 0.2 °, 24.65 ⁇ 0.2 °, 28.98 ⁇ 0.2 °, 31.60 ⁇ 0.2 °, and 36.61 ⁇ 0.2 °.
  • the X-ray powder diffraction pattern has 2 ⁇ values of 8.90 ⁇ 0.2°, 15.19 ⁇ 0.2°, 15.53 ⁇ 0.2°, 16.79 ⁇ 0.2°, 24.19 ⁇ 0.2°. Characteristic diffraction peaks at 25.70 ⁇ 0.2°, 32.08 ⁇ 0.2°, 33.98 ⁇ 0.2°, and 37.40 ⁇ 0.2°.
  • the velipani form A of the present invention has an X-ray powder diffraction pattern having a characteristic diffraction peak as shown in FIG.
  • the vilipani acid salt includes an organic acid salt or an inorganic acid salt, wherein the organic acid salt includes an organic acid mono-salt or an organic acid di-salt, and the inorganic acid-based salt includes a mineral acid.
  • the mono-salt or the inorganic acid di-salt; the mono-salt of the organic acid includes the mono-salt of the formic acid, the mono-salt of the acetic acid, the mono-salt of trifluoroacetic acid, the monosalt of trichloroacetic acid, etc.;
  • the dibasic salt of the organic acid includes the dibasic acetate and formic acid Di-salt, trifluoroacetic acid di-salt, tri-chloroacetic acid di-salt, etc.; inorganic acid-type single salt includes its hydrochloric acid mono-salt, monophosphate, sulfuric acid semi-salt, etc.; inorganic acid-type di-salt includes its dihydrochloride, sulfate And a diphosphate or the like; among them, a dihydrochloride salt or a monohydrochloride salt is preferred.
  • the aqueous solution of the inorganic salt includes an aqueous solution of sodium chloride, an aqueous solution of potassium chloride, an aqueous solution of sodium sulfate, an aqueous solution of potassium sulfate, and the like, and among them, an aqueous solution of sodium chloride is preferred.
  • the concentration of the aqueous sodium chloride solution is from 0 to 50%, preferably from 15 to 20%.
  • the concentration here is the mass concentration commonly used in the art.
  • the amount of the inorganic salt aqueous solution used in the present invention is not particularly limited, and the velipaniic acid salt can be completely dissolved to form a clear solution. Further, the dissolution of the present invention can be carried out at room temperature, such as 20 to 30 ° C and the like which are well known in the art.
  • the inorganic base includes sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, potassium hydrogencarbonate, sodium carbonate, sodium hydrogencarbonate or the like, and among them, sodium hydroxide or potassium hydroxide is preferred.
  • the pH and the crystallization temperature are both adjusted to -10 to 50 ° C, and preferably 0 to 40 ° C.
  • the time of the crystallization of the present invention is not particularly limited and may be 2 hours.
  • the invention is then filtered, washed, and dried in the manner conventional in the art to give the velipani form A.
  • the filter cake obtained by filtration can be washed with purified water; it can be dried under reduced pressure at 40 ° C.
  • a pharmaceutical composition comprising velimpani Form A and a pharmaceutically acceptable adjuvant.
  • the stability test of the velipani form A of the present invention was carried out: crystal form A was allowed to stand under accelerated conditions for 30 days, and its chemical stability and crystal form change were examined. The results are shown in Table 1.
  • Powder diffraction was performed using an X, Pert Pro MPDX-ray diffractometer, which was a copper wire operated at 40 KV and 30 mA. The sample was spread into thin slices and continuously scanned at a rate of 2° to 40° 2 ⁇ at a rate of 2° per minute.
  • the crystal form preparation method of the invention is simple, the yield is high, the purity is over 99%, and the crystal form quality is stable. It does not change crystal and does not absorb moisture. It is suitable for the manufacturing process of various preparations and is well dissolved.
  • the crystal form of the present invention has good biological activity, and in vitro dissolution is superior to the existing crystal form 1 and form 2, which contributes to improvement of oral bioavailability.
  • Figure 1 is an X-ray diffraction pattern of velipani form A.
  • Figure 2 is an infrared spectrum of velipani form A.
  • Figure 3 is a DSC-TGA map of velipani form A.
  • the obtained crystal form A was tested by XRPD, and its XRPD pattern is shown in Fig. 1. It was tested by infrared and DSC-TGA, and its infrared spectrum and DSC-TGA spectrum are shown in Fig. 2 and Fig. 3, respectively.
  • the stability test of the velipani form A of the present invention was carried out: crystal form A was allowed to stand under accelerated conditions for 30 days, and its chemical stability and crystal form change were examined. The results are shown in Table 1.
  • velipani diacetate 1.5 g was added to 15 mL of 15% aqueous sodium chloride solution at room temperature, dissolved by stirring, and filtered. Slowly add 15% sodium hydroxide aqueous solution to adjust the pH value. At this time, a small amount of solid precipitated.
  • the obtained crystal form was tested by XRPD, infrared and DSC-TGA, and the test results were basically the same as those of Figs. 1, 2 and 3.

Abstract

一种维利帕尼晶型A及其制备方法，该维利帕尼晶型A，其X粉末衍射图的2θ值在9.39±0.2°、13.38±0.2°、17.25±0.2°、17.70±0.2°、18.94±0.2°、21.79±0.2°、22.77±0.2°、24.65±0.2°、28.98±0.2°、31.60±0.2°、36.61±0.2°处有特征衍射峰。维利帕尼晶型A制备方法简单、收率高、纯度高、稳定性好，适合其制剂的制造过程。

Description

一种维利帕尼晶型A及其制备方法
本申请要求于2016年01月25日提交中国专利局、申请号为201610047524.5、发明名称为“一种维利帕尼晶型A及其制备方法”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明属于药物化学技术领域，具体涉及维利帕尼的晶型A及其制备方法。
背景技术
维利帕尼，英文名为Veliparib，化学名为2-((R)-2-甲基吡咯烷-2-基)-1H-苯并咪唑-4-甲酰胺，其化学结构式为如下式I化合物。
Figure PCTCN2017071619-appb-000001
维利帕尼是由Abbott原研，AbbVie开发的一种聚腺苷二磷酸核糖聚合酶(PARP)抑制剂，用于癌症治疗，主要是三阴乳腺癌和转移性鳞状非小细胞肺癌。2014年1月联合标准化疗作为一线新辅助疗法开展早期三阴乳腺癌的Ⅲ期临床实验；2014年3月，联合标准化疗作为一线新辅助疗法开展晚期或转移性鳞状非小细胞肺癌Ⅲ期临床实验；同时也在进行其他肿瘤的临床实验。DA授予维利帕尼在治疗恶性胶质瘤、上皮性卵巢癌、肝癌、转移性脑癌的孤儿药地位；EMA授予其在卵巢癌的孤儿药地位。预计2017年上市。
专利CN101821269报道了晶型2的晶型特征及制备方法，该方法将维利帕尼完全溶解在甲醇中，然后在约35℃减压浓缩即得。该方法制得样品收率高，但不具有除杂效果，且成品颜色较深；在浓缩过程，产品纯度明显下降，纯度约97％；经重现实验还发现，该方法得到单一2型晶的重现性差。专利CN101821270报道了晶型1的晶型特征及制备方法，该专利报道了两种制备晶型1的方法，方法一是将维利帕尼二盐酸盐溶于饱和碳酸氢钾溶液中，再用正丁醇提取、洗涤、浓缩后用异丙醇结晶。该方法操作繁琐，所用溶剂正丁醇、 正庚烷沸点高，浓缩过程高温容易引起产品纯度下降，同时该方法收率较低，约为30-40％，纯度约98％。方法二将维利帕尼二盐酸盐溶于水中，梯度调节PH值，缓慢析晶即得。该方法操作繁琐，pH值控制严格，工艺重现性难度较大，同时该工艺生产周期较长，生产成本较高。
本发明提供一种稳定的维利帕尼新晶型及其制备方法，相比现有晶型1与晶型2，本发明的晶型制备方法简便，收率高，纯度达99％以上，晶型质量稳定。
发明内容
本发明的目的在于提供了一种维利帕尼的晶型，该晶型在本发明的本文中被定义为维利帕尼晶型A。该晶型A具有制备方法简便，收率高，纯度高，晶型质量稳定的优点。
本发明的一种维利帕尼晶型A，其X粉末衍射图的2θ值在9.39±0.2°、13.38±0.2°、17.25±0.2°、17.70±0.2°、18.94±0.2°、21.79±0.2°、22.77±0.2°、24.65±0.2°、28.98±0.2°、31.60±0.2°、36.61±0.2°处有特征衍射峰。
上述本发明的维利帕尼晶型A，进一步的，其X-射线粉末衍射图谱的2θ值在8.90±0.2°、15.19±0.2°、15.53±0.2°、16.79±0.2°、24.19±0.2°、25.70±0.2°、32.08±0.2°、33.98±0.2°、37.40±0.2°处有特征衍射峰。
本发明的维利帕尼晶型A，其X-射线粉末衍射图谱具有如图1的特征衍射峰。
本发明还提供了一种制备维利帕尼晶型A的方法，包括将维利帕尼酸式盐溶解于水或无机盐水溶液中，用无机碱的水溶液调pH＝7～14，优选pH＝9～12，即析出晶体A。
上述本发明的方法，维利帕尼酸式盐包括有机酸式盐或无机酸式盐，其中，有机酸式盐包括有机酸式单盐或有机酸式二盐，无机酸式盐包括无机酸式单盐或无机酸式二盐；有机酸式单盐包括其甲酸单盐、乙酸单盐、三氟乙酸单盐、三氯乙酸单盐等；有机酸式二盐包括其乙酸二盐、甲酸二盐、三氟乙酸二盐、三氯乙酸二盐等；无机酸式单盐包括其盐酸单盐、单磷酸盐、硫酸半盐等；无机酸式二盐包括其二盐酸盐、硫酸盐、二磷酸盐等；其中优选其二盐酸盐或盐酸单盐。
上述本发明的方法，无机盐水溶液包括氯化钠水溶液，氯化钾水溶液、硫酸钠水溶液、硫酸钾水溶液等，其中优选氯化钠水溶液。
上述本发明的方法，氯化钠水溶液浓度为0～50％，优选15-20％。此处浓度为本领域常用的质量浓度。本发明对无机盐水溶液的用量没有特殊限制，能使维利帕尼酸式盐完全溶解形成澄清溶液即可。此外，本发明的溶解可在室温下进行，如本领域熟知的20～30℃等。
上述本发明的方法，无机碱包括氢氧化钠、氢氧化钾、氢氧化锂、碳酸钾、碳酸氢钾、碳酸钠、碳酸氢钠等，其中优选氢氧化钠、氢氧化钾。
上述本发明的方法，调节pH优选pH＝9～12。调节pH温度及析晶温度均为-10～50℃，其中优选0～40℃。本发明对析晶的时间没有特殊限制，可为2小时。然后，本发明按照本领域常规的方式过滤，洗涤，干燥，即得维利帕尼晶型A。其中，过滤所得滤饼可用纯化水洗涤；通过40℃减压干燥即可。
一种药物组合物，包含维利帕尼晶型A和药物可接受的辅料。
维利帕尼晶型A的稳定性考察。
本发明的维利帕尼晶型A的稳定性考察实验：将晶型A在加速条件下放置30天，考察其化学稳定性和晶型的变化，结果见表1。
表1 维利帕尼晶型A的稳定性考察结果
Figure PCTCN2017071619-appb-000002
上表1的结果表明，本发明的晶型A在高湿、高温、光照条件下化学稳定、晶型稳定。
用X，Pert Pro MPDX-射线衍射仪进行粉末衍射，X射线源是在40KV和30mA操作的铜丝。将样品铺成薄片，在2θ为2°～40°范围以每分钟2°的速率连续扫描。
本发明的晶型制备方法简便，收率高，纯度达99％以上，晶型质量稳定, 不转晶、不吸湿，适合各种制剂的制造过程，溶出好。
本发明的晶型具有良好的生物活性，体外溶出优于现有的晶型1和晶型2，有助于改善口服生物利用度。
附图说明
图1为维利帕尼晶型A的X射线衍射图谱。
图2为维利帕尼晶型A的红外图谱。
图3为维利帕尼晶型A的DSC-TGA图谱。
具体实施方式
结合以下实施例对本发明作进一步说明，可以使本领域技术人员更好的理解本发明，但不以任何方式限制本发明的范围。
晶型A的制备
实施例1
取维利帕尼二盐酸盐4.0g，室温下加到28mL 20％氯化钠水溶液中，搅拌溶清，过滤。缓慢滴加15％的氢氧化钠水溶液调pH＝9～11，此时有固体析出，室温搅拌2小时，过滤，滤饼用8mL纯化水洗涤，抽至断流，滤饼于40℃减压干燥，即得维利帕尼A晶型2.7g，收率为80.8％，纯度为99.74％。所得的晶型A经XRPD测试，其XRPD图谱见图1，并经红外和DSC-TGA测试，其红外图谱和DSC-TGA图谱分别见图2和图3。
本发明的维利帕尼晶型A的稳定性考察实验：将晶型A在加速条件下放置30天，考察其化学稳定性和晶型的变化，结果见表1。
表1 维利帕尼晶型A的稳定性考察结果
Figure PCTCN2017071619-appb-000003
上表1的结果表明，本发明的晶型A在高湿、高温、光照条件下化学稳定、晶型稳定。
实施例2
取维利帕尼二盐酸盐4.0g，室温下加到8mL纯化水中，搅拌溶清，过滤。缓慢滴加15％的氢氧化钾水溶液调节pH值，有固体析出，待pH＝9～11时，冰水浴搅拌析晶2小时，过滤，滤饼用8mL纯化水洗涤，抽至断流，滤饼于40℃减压干燥，得维利帕尼A晶型2.1g，收率为62.9％，纯度为99.46％。所得的晶型经XRPD、红外和DSC-TGA测试，其测试结果与图1、图2和图3基本一致。
实施例3
取维利帕尼二乙酸盐1.5g，室温下加到15mL 15％氯化钠水溶液中，搅拌溶解，过滤。缓慢滴加15％的氢氧化钠水溶液调节pH值，此时有少量固体析出，pH＝10～11时，冰水浴搅拌2小时，过滤，滤饼用6mL纯化水洗涤，滤饼于40℃减压干燥，即得维利帕尼A晶型0.6g，收率为60％，纯度为99.67％。所得的晶型经XRPD、红外和DSC-TGA测试，其测试结果与图1、图2和图3基本一致。
实施例4
取维利帕尼单盐酸盐5.0g，室温下加到30mL 15％氯化钠水溶液中，搅拌溶清，过滤。缓慢滴加15％的氢氧化钠水溶液，待反应液微变浑时，加入0.25g晶型A晶种，搅拌30分钟，继续滴加15％氢氧化钠溶液调节pH值，待pH＝10～12时，冰水浴搅拌2小时，过滤，滤饼用10mL纯化水洗涤，抽至断流，滤饼于40℃减压干燥，即得维利帕尼A晶型4.1g，收率为88.5％，纯度为99.53％。所得的晶型经XRPD、红外和DSC-TGA测试，其测试结果与图1、图2和图3基本一致。

Claims (10)

  1. 一种维利帕尼晶型A，其特征在于，其X粉末衍射图的2θ值在9.39±0.2°、13.38±0.2°、17.25±0.2°、17.70±0.2°、18.94±0.2°、21.79±0.2°、22.77±0.2°、24.65±0.2°、28.98±0.2°、31.60±0.2°、36.61±0.2°处有特征衍射峰。
  2. 如权利要求1所述的晶型A，其特征在于，其X粉末衍射图的2θ值在8.90±0.2°、15.19±0.2°、15.53±0.2°、16.79±0.2°、24.19±0.2°、25.70±0.2°、32.08±0.2°、33.98±0.2°、37.40±0.2°处有特征衍射峰。
  3. 一种制备权利要求1或2的晶型A的方法，其特征在于，包括将维利帕尼酸式盐溶解于水中或无机盐水溶液中，用无机碱的水溶液调溶液的pH＝7～14，即析出晶体A。
  4. 如权利要求3所述的方法，其特征在于，所述维利帕尼酸式盐包括其有机酸式盐或无机酸式盐。
  5. 如权利要求4所述的方法，其特征在于，有机酸式盐包括其甲酸单盐、甲酸二盐、乙酸单盐、乙酸二盐、三氟乙酸单盐、三氟乙酸二盐、三氯乙酸单盐或三氯乙酸二盐；无机酸式盐包括其单盐酸盐、二盐酸盐、半硫酸盐、硫酸盐、单磷酸盐或二磷酸盐；优选其二盐酸盐。
  6. 如权利要求3所述的方法，其特征在于，无机盐水溶液包括氯化钠水溶液，氯化钾水溶液、硫酸钠水溶液或硫酸钾水溶液，优选氯化钠水溶液。
  7. 如权利要求3所述的方法，其特征在于，所述用无机碱的水溶液调溶液的pH＝9～12。
  8. 如权利要求3所述的方法，其特征在于，无机碱包括氢氧化钠、氢氧化钾、氢氧化锂、碳酸钾、碳酸氢钾、碳酸钠或碳酸氢钠，优选为氢氧化钠或氢氧化钾。
  9. 如权利要求3所述的方法，其特征在于，析出晶体的温度为-10～50℃，其中优选为0～40℃。
  10. 一种药物组合物，包含权利要求1或2的晶型A，和药物可接受的辅料。
PCT/CN2017/071619 2016-01-25 2017-01-19 一种维利帕尼晶型a及其制备方法 WO2017129024A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610047524.5 2016-01-25
CN201610047524.5A CN106995436A (zh) 2016-01-25 2016-01-25 一种维利帕尼晶型a及其制备方法

Publications (1)

Publication Number Publication Date
WO2017129024A1 true WO2017129024A1 (zh) 2017-08-03

Family

ID=59397320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/071619 WO2017129024A1 (zh) 2016-01-25 2017-01-19 一种维利帕尼晶型a及其制备方法

Country Status (2)

Country Link
CN (1) CN106995436A (zh)
WO (1) WO2017129024A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155797A (zh) * 2005-04-11 2008-04-02 艾博特公司 在2-位上被一个季碳原子取代的1h-苯并咪唑-4-甲酰胺化合物是有效的parp抑制剂
CN101821270A (zh) * 2007-10-12 2010-09-01 雅培制药有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形1
CN101821269A (zh) * 2007-10-12 2010-09-01 雅培制药有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
CN104926793A (zh) * 2014-03-21 2015-09-23 成都海创药业有限公司 一种治疗肿瘤的化合物及其用途
CN105130961A (zh) * 2015-08-06 2015-12-09 苏州晶云药物科技有限公司 Abt-888的晶型b及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155797A (zh) * 2005-04-11 2008-04-02 艾博特公司 在2-位上被一个季碳原子取代的1h-苯并咪唑-4-甲酰胺化合物是有效的parp抑制剂
CN101821270A (zh) * 2007-10-12 2010-09-01 雅培制药有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形1
CN101821269A (zh) * 2007-10-12 2010-09-01 雅培制药有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
CN104926793A (zh) * 2014-03-21 2015-09-23 成都海创药业有限公司 一种治疗肿瘤的化合物及其用途
CN105130961A (zh) * 2015-08-06 2015-12-09 苏州晶云药物科技有限公司 Abt-888的晶型b及其制备方法和应用

Also Published As

Publication number Publication date
CN106995436A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
TWI597277B (zh) 一種酪胺酸激酶抑制劑的二馬來酸鹽的第ｉ型結晶及製備方法
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
EA034409B1 (ru) Способы получения кристаллического фенилацетата l-орнитина
EA018611B1 (ru) Твердые формы селективных модуляторов рецепторов андрогена
JP2022137223A (ja) セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス
CN106661025A (zh) 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法
TWI705060B (zh) 一種ｍｅｋ激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法
US10351574B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
CN112538123B (zh) 一种舒更葡糖钠晶型m
CN112538124B (zh) 一种舒更葡糖钠晶型
KR102090912B1 (ko) 신규한 결정형 형태의 에독사반 및 이의 제조방법
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
WO2017020869A1 (zh) 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用
WO2017129024A1 (zh) 一种维利帕尼晶型a及其制备方法
CN105859691A (zh) 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法
WO2012010092A1 (zh) 一种肽类物质的晶体及其制备方法和用途
CN103059013B (zh) 达沙替尼一水合物的晶型及其制备方法
WO2021000687A1 (zh) Pac-1晶型的制备方法
CN103113350A (zh) R-雷贝拉唑钠水合物的新晶型及制备方法和应用
EP3272734A1 (en) Ahu377 crystal form, preparation method and use thereof
ES2851499T3 (es) Proceso para fabricar una forma cristalina de gefitinib
CN116496247A (zh) 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型
CN105777656A (zh) 萘普替尼对甲苯磺酸盐的β晶型及制备方法和含有其的药物组合物
WO2021043200A1 (zh) 一种喹唑啉衍生物的制备方法及其结晶
CN104163769A (zh) 一种氯化丙酰左卡尼汀的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17743639

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17743639

Country of ref document: EP

Kind code of ref document: A1